Participants were evaluated as part of a clinical trial evaluating the safety and efficacy of simtuzumab (Gilead Sciences, Inc., Foster City, CA), a humanized monoclonal antibody that inhibits lysyl oxidase-like 2 (LOXL2), an enzyme that contributes to liver fibrosis by catalyzing collagen cross-linkage. Here, LOXL2 is linked to Hepatic fibrosis.